Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage

Moebius South Korea Japan Israel India

and follow us on LinkedIn & X (Formerly Twitter).

Disclaimer: Statements in this "document" describing Sun Pharma's and/or Moebius Medical's objectives, projections, estimates, expectations, plans or predictions, industry conditions, or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. Neither Sun Pharma nor Moebius Medical undertakes any obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

For further details, please contact:

Media 

Sun Pharma

Moebius Medical

Gaurav Chugh

Tel Direct: [phone]

Mobile: [phone]

Moshe Weinstein

Tel Direct: [phone]

Email: [e-mail]

Email: [e-mail]

Investors

Sun Pharma

Dr. Abhishek Sharma

Tel Direct: [phone]

Mobile: [phone]

Email: [e-mail]

View original content:https://www.prnewswire.co.uk/news-releases/sun-pharma-and-moebius-medical-announce-dual-publications-on-mm-iis-phase-2b-clinical-trial-results-and-mechanism-of-action-in-osteoarthritis-and-cartilage-302437002.html

@ prnewswire.co.uk